Literature DB >> 24723165

Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration.

Tae Gon Lee1, Jae Hui Kim, Young Suk Chang, Chul Gu Kim, Jong Woo Kim.   

Abstract

PURPOSE: To investigate factors influencing exudation recurrence following cataract surgery in patients already treated with anti-vascular endothelial growth factor (VEGF) agents for exudative age-related macular degeneration (AMD).
METHODS: A retrospective review of medical records was performed for patients who underwent cataract surgery and had been previously treated with anti-VEGF for exudative AMD. Visual acuity was examined before surgery and 1 and 6 months after surgery. The time between diagnosis and surgery, and the exudation-free period before surgery were examined and compared between patients who had exudation recurrence and those that did not.
RESULTS: Thirty-nine eyes of 39 patients were included in analyses. The logarithm of the minimum angle of resolution visual acuity was 1.02 ± 0.58 and had significantly improved 1 month (0.81 ± 0.62, P < 0.001) and 6 months (0.85 ± 0.64, P = 0.001) following surgery. Both the diagnosis-to-surgery period (P = 0.001) and the preoperative exudation-free period (P < 0.001) were significantly longer in patients without recurrence than in patients with recurrence.
CONCLUSIONS: Cataract surgery was beneficial in patients previously treated with anti-VEGF for exudative AMD. Our data suggests that cataract surgery should be performed after a sufficiently long exudation-free period to minimize exudation recurrence. But larger prospective studies are required to draw definitive clinical guidelines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24723165     DOI: 10.1007/s00417-014-2624-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

1.  Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes.

Authors:  Maher Saleh; Mehdi Kheliouen; Eliza Tebeanu; Laurent Ballonzoli; Tristan Bourcier; Claude Speeg-Schatz; David Gaucher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-22       Impact factor: 3.117

2.  Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration.

Authors:  Ramu Muniraju; Jayashree Ramu; Sobha Sivaprasad
Journal:  Ophthalmologica       Date:  2013-04-30       Impact factor: 3.250

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Phacoemulsification in eyes with neovascular AMD treated with anti-VEGF injections.

Authors:  Maria Muzyka-Wozniak
Journal:  Eur J Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 2.597

5.  Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration.

Authors:  Alejandro Oliver-Fernandez; Jeff Bakal; Shaun Segal; Gaurav K Shah; Ashish Dugar; Sanjay Sharma
Journal:  Can J Ophthalmol       Date:  2005-06       Impact factor: 1.882

6.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

7.  Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery.

Authors:  Lebriz Ersoy; Albert Caramoy; Tina Ristau; Bernd Kirchhof; Sascha Fauser
Journal:  Br J Ophthalmol       Date:  2013-04-23       Impact factor: 4.638

8.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Authors:  Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2009-04-18       Impact factor: 5.258

9.  Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration.

Authors:  Philipp S Muether; Robert Hoerster; Manuel M Hermann; Bernd Kirchhof; Sascha Fauser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-11       Impact factor: 3.117

10.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079

View more
  4 in total

1.  Effect of cataract surgery in patients with neovascular age-related macular degeneration: further evidence from disciform scars.

Authors:  Mücella Arıkan Yorgun; Yasin Toklu; Meltem Ece Kar; Basri Hasan Çakmak
Journal:  Int Ophthalmol       Date:  2017-03-02       Impact factor: 2.031

Review 2.  Recurring themes during cataract assessment and surgery.

Authors:  Shruti Chandra; Sobha Sivaprasad; Paul G Ursell; Khayam Naderi; David O'Brart; Amar Alwitry; Mayank A Nanavaty
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 4.456

3.  Cost-Utility Analyses of Cataract Surgery in Advanced Age-Related Macular Degeneration.

Authors:  Yingyan Ma; Jiannan Huang; Bijun Zhu; Qian Sun; Yuyu Miao; Haidong Zou
Journal:  Optom Vis Sci       Date:  2016-02       Impact factor: 1.973

4.  Effect of Phacoemulsification on Visual Acuity and Macular Morphology in Patients with Wet Age-Related Macular Degeneration.

Authors:  Małgorzata Figurska; Agnieszka Bogdan-Bandurska; Marek Rękas
Journal:  Med Sci Monit       Date:  2018-09-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.